Compounds found in cannabis  could provide a new roadmap for treating the world’s most common chronic liver disorder, according to a study released by the Hebrew University of Jerusalem. The research, published in the British Journal of Pharmacology, found that cannabidiol (CBD) and cannabigerol (CBG) significantly reduced liver fat and improved metabolic health in experimental models. CBD is the more widely studied non-intoxicating cannabinoid, while CBG is a less common “precursor”